OUR DEVELOPMENT PORTFOLIO
Updated September 2021
-
Oncology -
Cardiometabolism -
Neuroscience -
immuno-inflammation
Phase 1
Haematological malignancies
Mcl1 inhibitor
Haematological malignancies
Bcl2 inhibitor
Haematological malignancies
DHODH inhibitor
Solid tumors
Anti CD73
Solid tumors
MAT2A inhibitor
Solid tumors
NKG2A
Solid tumors
PDLx41 BB
Solid tumors
Anti PD1xAnti TIM3
Relapsed or refractory myelodysplastic syndrome (MDS)
Tibsovo® (pre-registration)
Grade 2-3 Gliome, combo
Vorasidenib
Phase 2
Sjögren disease
Anti IL7R
Phase 3
Colorectal cancer, 1st line Combo
Lonsurf®
Colorectal cancer, 3rd line Combo
Lonsurf®
Colorectal cancer
Anti EGFR combo Lonsurf®
Acute myeloid leukemia (AML) IC-ineligible, 1st line
Tibsovo®
Acute myeloid leukemia (AML) IC-eligible, 1st line
Tibsovo®
Low-grade Glioma
Vorasidenib